

ASX Announcement



Medibio Limited – 7 September 2018

Medibio Hosts Call to Discuss Clinical Validation Study

Sydney, Australia and Minneapolis, MN USA – 7 September 2018: Medibio Limited (MEB or the Company)(ASX: MEB)(OTCQB: MDBIF), a mental health technology company, today announced it will host a teleconference to discuss the recent clinical validation study results, released earlier this week. Specific topics will include the importance of this study to our technology, a general overview of the study and results, supporting methodology, and comparison to prior studies.

Participants on the call include:

- Brian Mower, CFO, Interim CEO, Medibio
- Archie Defillo, Chief Medical Officer, Medibio
- Franklyn Prendergast, M.D., Ph.D., Chairman of Medibio Scientific Advisory Board
- Marie Olseth, M.D., Medibio Scientific Advisory Board member currently in private practice as a Board Certified Adult Psychiatrist.
- Amy Fowler, RAC, JD, Gardner Law, legal counsel for Medibio focused on regulatory affairs
- Melissa Martinson, MS, Ph.D., President of Technomics Research, providing statistical analysis for clinical study data

The teleconference is scheduled for 10:00 am Australian Eastern Standard time on Wednesday, 12 September 2018. To dial in to the conference please use either of the telephone numbers or the webcast URL listed below.

Australia: +61 2 9091 7604
United States: +1 (951) 384-3421
Access Code: 987-396-698

Registration URL: <https://attendee.gotowebinar.com/register/1219224648071516930>

Please note that all questions can be submitted via investors@medibio.com.au and will be addressed throughout the call or specifically at the end of the call if required.

About Medibio Limited

Medibio (ASX: MEB) (OTCQB: MDBIF) is a mental health technology company that has pioneered the use of objective digital biomarkers to assist in the screening, diagnosing, monitoring and management of depression and other mental health conditions. The company was founded in Australia, with offices located in Melbourne (Vic), Perth (Wa) and U.S. offices in Minneapolis, MN. Medibio is listed on the

ASX Announcement



Medibio Limited – 7 September 2018

Australian Securities Exchange Ltd and trades on the OTCQB Venture Market. Investors can find additional information on www.otcmarkets.com and www.asx.com.au

Further Information:

Website: www.medibio.com.au

Medibio Enquiries:

Josh Purdy
Senior Public Relations Manager
Medibio Limited
josh.purdy@medibio.com.au
T: +1 952 314 1216

Australian Media Enquiries:

Peter Taylor
NWR Communications
peter@nwrcommunications.com.au
T: +61 (0) 412 036 231